Submitted by Anonymous (not verified) on 9 October 2023 - 13:16
Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Asthma, Date of authorisation: 19/09/2022, Revision: 8, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Asthma, Date of authorisation: 19/09/2022, Revision: 8, Status: Authorised